Clinical trial
Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus…
NCT00195533 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00195533 |
|---|---|
| Title | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients |
| Official title | Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Collaborators | PETHEMA (Program for the Study and Treatment of Haematological Malignances) |
| Status | Completed |
| Study type | Observational |
| Conditions | Hematological Malignancy, Leukemia, Myelodysplasia, Lymphoma, Myeloma, Stem Cell Transplantation |
| Intervention type | Drug |
| Interventions | piperacillin-tazobactam, glycopeptide |
| Enrollment | 801 |
| Start date | Jul 1, 2001 |
| Primary completion | Mar 1, 2005 |
| Completion | Mar 1, 2005 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 16, 2009 |
| Countries | Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: